Dianthus Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $1,326 | $2,172 | $1,863 | $874 |
Gross Profit | 1,326 | 2,172 | 1,752 | 767 |
EBITDA | -31,838 | -29,784 | -22,204 | -17,737 |
EBIT | -31,916 | -29,900 | -22,315 | -17,844 |
Net Income | -28,440 | -25,174 | -17,607 | -13,748 |
Net Change In Cash | 1,326 | 2,172 | 1,863 | 874 |
Free Cash Flow | -27,475 | -8,422 | -14,545 | -14,973 |
Cash | 22,792 | 33,671 | 314,169 | 329,724 |
Basic Shares | 34,236 | 34,236 | 34,227 | 25,665 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $6,235 | $2,826 | $6,417 | $1,476 |
Gross Profit | 6,235 | 2,471 | 6,270 | -544 |
EBITDA | -101,864 | -48,174 | -29,558 | -13,086 |
EBIT | -48,529 | -29,705 | -15,106 | |
Net Income | -84,969 | -43,555 | -28,476 | -13,109 |
Net Change In Cash | 6,235 | 2,826 | 6,417 | 1,476 |
Free Cash Flow | -78,285 | -36,971 | -29,209 | -9,937 |
Cash | 22,792 | 132,325 | 15,365 | 7,638 |
Basic Shares | 34,236 | 5,153 | 3,747 | 3,434 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.81 |
2024-09-30 | -$0.72 |
2024-06-30 | -$0.51 |
2024-03-31 | -$0.54 |
